During the first year and a half of the pandemic, a handful of small companies developing next-generation Covid-19 vaccines hired lobbyists in hopes of winning contracts to fund research, manufacturing and testing. Megan R. Wilson talks with host Ben Leonard about why, nearly three years in, many have abandoned their Washington, D.C., footprint.
During the first year and a half of the pandemic, a handful of small companies developing next-generation Covid-19 vaccines hired lobbyists in hopes of winning contracts to fund research, manufacturing and testing. Megan R. Wilson talks with host Ben Leonard about why, nearly three years in, many have abandoned their Washington, D.C., footprint.